FLOW (NEJM 2024) showed semaglutide cut major kidney and cardiovascular events by ~24% in people with type 2 diabetes and chronic kidney disease, and was stopped early for efficacy.
In the FLOW trial (New England Journal of Medicine, 2024), once-weekly semaglutide reduced the risk of major kidney disease events and cardiovascular death by approximately 24% in adults with type 2 diabetes and chronic kidney disease. An independent committee stopped the trial early for efficacy. FLOW used FDA-approved semaglutide under medical supervision — not compounded semaglutide.
Medical & FDA note: Educational only, not medical advice. Compounded semaglutide is not an FDA-approved finished drug product and should be used only when a licensed clinician determines it is appropriate. Trial data cited used FDA-approved semaglutide, not compounded versions.
FLOW (Evaluate Renal Function with Semaglutide Once Weekly) randomized adults with type 2 diabetes and chronic kidney disease to once-weekly semaglutide or placebo, on top of standard care including renin-angiotensin-system blockade.
The primary outcome was a composite of major kidney events: onset of kidney failure, a sustained drop in kidney function of at least 50% (eGFR), or death from kidney or cardiovascular causes. Following kidney-protection benefits seen in earlier diabetes trials, FLOW was designed specifically to test kidney outcomes.
Across the components of the composite, semaglutide was associated with fewer kidney-function declines, fewer kidney-failure events, and fewer cardiovascular deaths. Secondary analyses also showed a slower annual decline in eGFR — a marker of how fast kidney function is lost over time — favoring semaglutide.
Approximate relative risk reductions as reported for FLOW (NEJM 2024); exact figures and confidence intervals are in the primary publication. Directional, for orientation only.
The mechanisms are still being characterized, but proposed contributors include weight reduction, lower blood pressure, improved glucose control, reduced inflammation, and direct effects on kidney blood flow (intraglomerular pressure). The kidney benefit in FLOW appeared only partly explained by weight and glucose changes, suggesting additional pathways.
FLOW's population was specific: type 2 diabetes plus established chronic kidney disease. The results do not automatically transfer to people without diabetes or without kidney disease, and they do not establish that everyone should take semaglutide for kidney protection. Decisions about kidney or cardiovascular use are individual and clinician-directed.
FLOW, like the STEP and SELECT programs, was conducted with the FDA-approved product. Compounded semaglutide is not FDA-approved and was not studied in FLOW; you cannot assume identical outcomes. If you and your clinician consider compounded semaglutide, pharmacy quality and oversight matter, and any organ-protection rationale should rest on the branded-drug evidence under medical supervision.
Because kidney and cardiovascular benefits accrue over years of continuous treatment, predictable pricing supports the adherence those outcomes depend on. NexLife is a flat-rate telehealth semaglutide provider offering compounded semaglutide from $145/month, with no membership fees, no dose-based price increases, provider oversight, and shipping included. See the affordability analysis below for how flat-rate pricing compares on a true 12-month basis.